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Colicky baby? 
Here’s a surprising remedy
When distraught parents seek your help because 
their breastfed infant won’t stop crying, recommend 
probiotics. 
PRACTICE CHANGER 
Suggest that parents of colicky breastfed in-
fants try probiotics (Lactobacillus reuteri), 
which can signifi cantly reduce daily crying 
time with no adverse eff ects.1
STRENGTH OF RECOMMENDATION: 
A: A good-quality randomized controlled 
trial (RCT). 
Savino F, Cordisco L, Tarasco V, et al. Lactobacillus reuteri DSM 17938 
in infantile colic: a randomized, double-blind, placebo-controlled trial. 
Pediatrics. 2010;126:e526-e533.
ILLUSTRATIVE CASE
The parents of an otherwise healthy 10-week-
old breastfed baby girl bring her in for the 
second time in 2 weeks because of her in-
consolable crying.  Physical examination and 
work-up remain normal, and you again diag-
nose colic.  What can you suggest to help de-
crease the baby’s crying, other than the usual 
dietary advice? 
Colic aff ects up to 28% of infants, caus-ing considerable stress for parents and for their health care providers.2 
Indeed, in the fi rst 3 months of a baby’s life, 
crying is the No. 1 reason for pediatric visits.3 
Parents often perceive—incorrectly—that the 
inconsolable crying is either a sign of serious 
illness or a result of poor parenting skills.4  
A distressing problem, with few remedies
Despite the ubiquity and frustration that ac-
company colic, its exact etiology remains un-
clear and eff ective treatments remain elusive. 
With very little quality evidence to support 
interventions for colicky infants, we often 
have nothing more than grandmotherly ad-
vice to off er parents of babies with this vexing 
condition.
Current guidelines recommend only one 
strategy for breastfeeding mothers: a low-
allergen diet.5 However, recent studies sug-
gest that low counts of intestinal lactobacilli 
may play a role in colic and have document-
ed improved symptoms after treatment with 
lactobacilli compared with treatment with 
simethicone.6-8 Infant formulas that contain 
probiotics are now available, as a result. 
Although the results of the recent studies 
have been promising, they were not double-
blinded or placebo-controlled. Th e study de-
tailed here is the fi rst to provide compelling 
evidence for a safe intervention for colicky 
breastfed infants.
STUDY SUMMARY
Lactobacilli cut crying time
In a randomized, double-blinded, placebo-
controlled trial, Savino et al randomly as-
signed 50 exclusively breastfed colicky 
infants ages 2 to 16 weeks to receive either 
L reuteri DSM 17 938 (108 colony-forming 
units) or placebo daily for 21 days.  Diagnosis 
of colic was made according to the modifi ed 
Wessel’s criteria—fussy crying for ≥3 hours 
per day for ≥3 days per week in the week be-
fore enrollment. Th eir mothers were told to 
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avoid ingesting cow’s milk during the course 
of the study.
Term infants adequate for gestational age 
were eligible for inclusion in the study.  Exclu-
sion criteria included evidence of chronic ill-
ness or gastrointestinal disorders, any intake of 
probiotics and/or antibiotics in the week pre-
ceding recruitment, and any formula feeding.
Parents and providers were blinded dur-
ing the study, and they reported daily crying 
time, stool characteristics, adverse events, 
and growth patterns. An identical looking 
and tasting triglyceride oil without live bac-
teria was used in the placebo group. Each in-
fant received 5 drops of L reuteri or placebo 
each morning 30 minutes before the morning 
feeding.  
Th e primary outcome was a reduction of 
average crying time to <3 hours a day by Day 
21.  A secondary outcome was the number of 
infants in each group who experienced a 50% 
decrease in the daily average crying time from 
baseline on Days 7, 14, and 21 of the study.  
Initially, the babies were divided equally 
between the control and intervention groups, 
but 4 participants in the control group were 
later excluded from analysis (1 had fever, 
1 had refl ux, and the parents of 2 infants did 
not complete the analysis).
At the time of enrollment, no signifi cant 
diff erences were noted between the interven-
tion and control groups regarding type of deliv-
ery, sex, age, family history of gastrointestinal 
disorders, growth parameters, and median dai-
ly crying time (370 minutes for the probiotics 
group vs 300 minutes for the placebo group). 
By Day 21, the number of infants with cry-
ing times >3 hours was signifi cantly lower in 
the treatment group compared with the pla-
cebo group (4 vs 12, respectively; P=.009). At all 
stages in the study, crying time for those in the 
treatment group was less than in the placebo 
group; median crying times for the interven-
tion group were 95, 60, and 35 minutes per day, 
vs 185, 150, and 90 minutes for the controls, at 
7, 14, and 21 days, respectively. 
Th e number of infants with a 50% reduc-
tion in crying time was signifi cantly greater in 
the treatment group than in the placebo group 
on Days 7, 14, and 21 (TABLE), although both 
groups saw an increase in the number of chil-
dren whose average crying time had dropped 
by 50% as time went by. Th e number needed 
to treat to reduce crying time by 50% on Day 
21 was 4. 
Th ere were no diff erences between the 
groups in growth, weight gain, frequency of 
stools, or incidence of regurgitation or consti-
pation. No adverse events related to the treat-
ment were reported.  
WHAT’S NEW
We have an evidence-based 
remedy that’s safe and effective 
Th is study represents the fi rst randomized, 
double-blinded, placebo-controlled inves-
tigation of probiotics to reduce infant colic. 
Th e researchers’ focus on patient-oriented 
outcomes and their solid study design move 
the notion of probiotics’ effi  cacy from con-
jecture to evidence.  Furthermore, the study 
documents the safety of the intervention in 
the treatment group. Th is study increases our 
evidence-based armamentarium for treating 
colic, and family physicians should consider 
prescribing probiotics for healthy breastfed 
infants with colic. 
CAVEATS
Will it work for 
bottle-fed infants?
Th is study was conducted in exclusively breast-
fed, healthy infants whose mothers avoided di-
etary cow’s milk, which limits its applicability 
to a more general infant population. Th e study 
was funded by the makers of the probiotic, but 
the rigorous study design with random alloca-
tion, double-blind design, and intention-to-
treat analysis makes bias unlikely. Although 
Have you 
recommended 
probiotics for infants 
with colic? 
■ Frequently 
■  Sometimes 
■  Rarely or never
■  No, but I will now
■ Other _____________
Go to jfponline.com
and take our instant poll 
INSTANT 
POLL
QUESTION
TABLE  
Babies respond* to probiotics
Day of 
study
L reuteri
n=25 (%)
Placebo
n=21 (%)
P 
value
7 20 (80) 8 (36) .006
14 24 (96) 13 (62) .007
21                             24 (96) 15 (71) .036
*An infant with a decrease in daily average crying time of 
50% from baseline was defi ned as a responder.
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References
no adverse eff ects were reported during this 
study, there is little available evidence about 
the long-term eff ects of probiotics in infants. 
As L reuteri are naturally occurring gut bacte-
ria, however, it seems unlikely that it would be 
harmful in the long term. 
CHALLENGES TO IMPLEMENTATION
Parents will need to purchase 
the probiotics 
As with any non–FDA-regulated product, it 
will be important to guide patients toward rep-
utable manufacturers to ensure homogeneity 
of dosing. A 29-day supply of BioGaia probiotic 
drops (100 million units once a day), which 
costs $37 according to the manufacturer’s Web 
site, http://www.biogaia.com/consumer/
biogaia-probiotic-products/probiotic-drops, 
should be aff ordable for most parents. Other-
wise, little stands in the way of using this ther-
apy to reduce the crying and subsequent stress 
associated with infant colic.                JFP
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